The FDA originally approved Otulfi as a biosimilar in October 2024 based on clinical data that demonstrated the product was highly similar to Stelara.

Taiwan FDA approves Chugai Pharma’s PiaSky for subcutaneous treatment of patients with paroxysmal nocturnal hemoglobinuria: Tokyo Tuesday, May 20, 2025, 10:00 Hrs [IST] Chugai P ...

A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.

Research agreement is evaluating feasibility of applying Rani's oral delivery technology to Chugai's antibodies against undisclosed targets - SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani ...

Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced today that the U.S. Food and Drug Administration (FDA) designated Otulfi® (ustekinumab-aauz) as an interchangeable ...

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a ...

CEO Dan O'Connell reported that Acumen completed enrollment of its 542-participant Phase 2 ALTITUDE-AD study evaluating Sabirnetug for early Alzheimer’s disease, stating, "We completed enrollment of ...

The autoinjector offers potential pain relief and is designed for self-administration, eliminating the need for refrigeration ...

The company targets topline results in late 2026 and continues to advance both intravenous and subcutaneous Sabirnetug development, supported by a strong cash position expected to fund operations ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

In THRIVE, Abrams' group recruited participants with moderate-to-severe active thyroid eye disease with proptosis at least 3 ...

Q1 2025 Earnings Call Transcript May 13, 2025 Acumen Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...